• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Tolvaptan reduces eGFR decline in patients with polycystic kidney disease

byDayton McMillan
November 17, 2017
in Chronic Disease, Nephrology, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Estimated glomerular filtration rate (eGFR) declined less over one year of treatment for patients with later-stage autosomal dominant polycystic kidney disease (ADPKD) taking tolvaptan than those taking placebo.

2. Liver enzyme increases above 3 times the upper limit of normal (ULN) and serious liver-related events occurred more in the tolvaptan group than the placebo group.

Evidence Rating: 1 (Excellent)

Study Rundown: ADPKD is a condition which results in vasopressin sensitive sections of the renal tubule proliferating and expressing proinflammatory signals, ultimately leading to renal damage. Various methods for reducing vasopressin action in the renal tubule have showed benefit in protecting kidney function and prolonging survival in both animal and human studies. Tolvaptan is a vasopressin V2-receptor antagonist which has previously shown efficacy in reducing eGFR decline in early-stage ADPKD, and its efficacy for later-stage disease is of interest. This phase 3 trial included patients with stage 2 to early stage 4 ADPKD and randomized them to receive tolvaptan or placebo for 12 months. The primary endpoint was the change in eGFR from baseline. Patients in the tolvaptan group had significantly lower reductions in eGFR from baseline compared to the placebo group. Tolvaptan treated patients also experienced a greater number of liver enzyme elevations and serious hepatic adverse events. This study indicates efficacy of tolvaptan for decreasing eGFR decline in later-stage ADPKD, though long-term effectiveness is not yet understood.

Click to read the study, published in NEJM

Relevant Reading: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia

RELATED REPORTS

2 Minute Medicine Rewind October 28 – November 3, 2013

In-Depth [randomized controlled trial]: This phase 3 multinational randomized clinical trial enrolled 1370 patients from 2014 to 2016. Eligible patients had stage 2 to early stage 4 ADPKD as determined by eGFR and were randomized in a 1:1 manner, stratified by eGFR, age, and total kidney volume, to receive either tolvaptan (n = 683) or placebo (n = 687). Monthly laboratory studies were performed during the study assessing creatinine, liver enzymes, and bilirubin. The primary trial endpoint was the change in eGFR from baseline to the trial conclusion, with a secondary endpoint being the slope of eGFR change.

The mean change in eGFR over 1 year was -2.34 mL/min/1.73m2 (95%CI, -2.81 to -1.87) in the tolvaptan group and -3.61 mL/min/1.73m2 (95%CI, -4.08 to -3.17) in the placebo group. Comparison showed a slower decline in the tolvaptan group vs the placebo group (difference of 1.27 mL/min/m2; 95%CI, 0.86 to 1.68, p < 0.001). Subgroup analysis indicated an eGFR benefit in the tolvaptan group regardless of patient sex, baseline eGFR, or stage of ADPKD. The slope of eGFR decline was significantly less in the tolvaptan group compared to the placebo group (difference of 1.01 mL/min/1.73m2; 95%CI, 0.62 to 1.40; p < 0.001). Serious hepatic related adverse events and elevations of liver enzymes greater than 3 times the ULN occurred in more patients in the tolvaptan group. This study does suggest that eGFR is better maintained for later-stage ADPKD patients on tolvaptan than those treated with placebo, though long term effects of both treatment and liver related complications require further investigation.

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: autosomal dominant polycystic kidney disease
Previous Post

Heart failure readmission prevention program may have inadvertent consequences

Next Post

Nonmedical prescription drug use associated with dating violence in adolescents

RelatedReports

Patient transfers to trauma centers often unnecessary
Cardiology

2 Minute Medicine Rewind October 28 – November 3, 2013

November 4, 2013
Next Post
AAP reaffirms support for adolescents’ rights to confidential reproductive care

Nonmedical prescription drug use associated with dating violence in adolescents

Long-term outcomes for off-pump and on-pump CABG are similar

Cluster analysis identifies phenotype groups for atrial fibrillation with unique clinical outcomes

Participation in sports and exercise linked to lower opioid use

Providing unlimited, immediate access to opioid agonist therapy to people with opioid use disorders could save billions and improve outcomes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mazdutide significantly reduces weight in adults with overweight or obesity
  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
  • Inebilizumab improves outcome in patients generalized myasthenia gravis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.